Quick Answer
INTEGRATED BIOPHARMA INC reported Total Revenue of $43.71 million for fiscal year 2018.
INTEGRATED BIOPHARMA INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | $808.0K +621.4% |
$112.0K +429.4% |
-$34.0K -100.9% |
$3.84M -52.1% |
$8.01M +95.1% |
$4.11M +143.4% |
| Diluted EPS | $0.03 | $0.00 | $0.00 -100.0% |
$0.12 -52.0% |
$0.25 +92.3% |
$0.13 +116.7% |
| Total Assets | $24.90M -5.0% |
$26.21M +3.1% |
$25.43M +0.7% |
$25.25M -0.7% |
$25.44M +10.9% |
$22.94M +15.9% |
| Cash and Equivalents | $3.62M +115.6% |
$1.68M +27.4% |
$1.32M +297.6% |
$331.0K +57.6% |
$210.0K -47.8% |
$402.0K -15.4% |
| Long-Term Debt | — | — | $7.0K -86.8% |
$53.0K | $0.00 -100.0% |
$1.44M -47.2% |
| Stockholders Equity | $20.32M +5.6% |
$19.24M +2.0% |
$18.86M +1.5% |
$18.57M +29.6% |
$14.33M +136.3% |
$6.07M +220.5% |
| Operating Income | $2.02M +704.8% |
$251.0K +109.2% |
$120.0K -95.6% |
$2.75M -52.5% |
$5.78M +77.5% |
$3.26M +20.5% |
| Gross Profit | $5.56M +43.2% |
$3.88M -4.4% |
$4.06M -38.0% |
$6.55M -30.9% |
$9.48M +40.9% |
$6.73M +8.1% |
| Shares Outstanding | 31.06M +3.2% |
30.10M +0.5% |
29.95M +0.0% |
29.95M +0.5% |
29.80M +0.5% |
29.65M +0.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2018 | $10.30M | +5.5% | -2.6% |
| Net Income | December 31, 2025 | -$762.0K | -756.9% | -719.5% |
| Diluted EPS | December 31, 2025 | -$0.03 | -400.0% | — |
| Total Assets | December 31, 2025 | $23.55M | -8.2% | -7.8% |
| Cash and Equivalents | December 31, 2025 | $5.31M | +115.9% | +12.3% |
| Long-Term Debt | March 31, 2024 | $0.00 | -100.0% | -100.0% |
| Stockholders Equity | December 31, 2025 | $19.77M | +0.2% | -3.5% |
| Operating Income | December 31, 2025 | -$914.0K | -552.5% | -660.7% |
| Gross Profit | December 31, 2025 | $29.0K | -97.5% | -97.2% |
| Shares Outstanding | December 31, 2025 | 31.09M | +2.6% | +0.1% |
- INTEGRATED BIOPHARMA INC reported Total Revenue of $43.71 million for fiscal year 2018.
- INTEGRATED BIOPHARMA INC showed a decrease of -6.9% in Total Revenue compared to the prior fiscal year.
- INTEGRATED BIOPHARMA INC reported Net Income of $808.0 thousand for fiscal year 2025.
- INTEGRATED BIOPHARMA INC showed an increase of +621.4% in Net Income compared to the prior fiscal year.
- INTEGRATED BIOPHARMA INC reported Diluted EPS of $0.03 per share for fiscal year 2025.
- INTEGRATED BIOPHARMA INC reported Total Assets of $24.90 million for fiscal year 2025.
- INTEGRATED BIOPHARMA INC showed a decrease of -5.0% in Total Assets compared to the prior fiscal year.
- INTEGRATED BIOPHARMA INC reported Cash and Equivalents of $3.62 million for fiscal year 2025.
- INTEGRATED BIOPHARMA INC showed an increase of +115.6% in Cash and Equivalents compared to the prior fiscal year.
- INTEGRATED BIOPHARMA INC reported Long-Term Debt of $7.0 thousand for fiscal year 2023.
- INTEGRATED BIOPHARMA INC showed a decrease of -86.8% in Long-Term Debt compared to the prior fiscal year.
- INTEGRATED BIOPHARMA INC reported Stockholders Equity of $20.32 million for fiscal year 2025.
- INTEGRATED BIOPHARMA INC showed an increase of +5.6% in Stockholders Equity compared to the prior fiscal year.
- INTEGRATED BIOPHARMA INC reported Operating Income of $2.02 million for fiscal year 2025.
- INTEGRATED BIOPHARMA INC showed an increase of +704.8% in Operating Income compared to the prior fiscal year.
- INTEGRATED BIOPHARMA INC reported Gross Profit of $5.56 million for fiscal year 2025.
- INTEGRATED BIOPHARMA INC showed an increase of +43.2% in Gross Profit compared to the prior fiscal year.
- INTEGRATED BIOPHARMA INC reported Shares Outstanding of 31.06 million shares for fiscal year 2025.
- INTEGRATED BIOPHARMA INC showed an increase of +3.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: